| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3.9M | +7.4% | -0.6% |
| SG&A Expense | $3.3M | -63.2% | -12.8% |
| Operating Income | -$11.8M | +5.6% | -23.0% |
| Net Income | -$11.9M | +8.1% | -26.3% |
| EPS (Basic) | -$0.12 | +40.0% | +14.3% |
| EPS (Diluted) | -$0.12 | +40.0% | +14.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $46.7M | +9.8% | +264.8% |
| Short-term Investments | $35.9M | +3810.7% | -43.6% |
| Current Assets | $86.7M | +87.7% | +7.0% |
| Total Assets | $87.8M | +85.1% | +6.1% |
| Current Liabilities | $10.5M | +13.4% | +100.2% |
| Long-term Debt |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$36.3M | — | — |
| Capital Expenditures | $19K | — | — |
| Investing Cash Flow | $8.5M | — | — |
| Financing Cash Flow | $49.1M | — | — |
| Free Cash Flow | -$36.3M | — | — |
| $56.2M |
| +1.8% |
| +7.2% |
| Total Liabilities | $67.2M | +3.2% | +14.6% |
| Stockholders' Equity | $20.5M | +215.5% | -14.6% |